Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing

Stock Track

2024-12-23

Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.

The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.

Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1137770145"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137770145\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1137770145?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137770145","market":"us","top_or_hot":-1,"title":"Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing","media":"Stock Track","content":"<p>Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.</p>\n\n<p>The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.</p>\n\n<p>Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-12-23 20:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.</p>\n\n<p>The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.</p>\n\n<p>Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVXL","symbol_name":"Anavex Life Sciences Corp.","start_time":0,"source_url":"","article_id":"1137770145","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137770145","pubTimestamp":1734956668,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Anavex Life Sciences Corp.  witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.The European Medicines Agency  has accepted for review Anavex's Marketing Authorization Application  for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVXL":"Anavex Life Sciences Corp."},"translate_title":"EMA接受阿尔茨海默氏症药物申请后，Anavex Life Sciences盘前股价飙升9.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":1},"content_text":"Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.\nThe European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.\nBlarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}